Astellas Pharma (ALPMY) announced the Food and Drug Administration issued a Complete Response Letter regarding the supplemental new drug ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

"Astellas stands by the clinical profile of Izervay, the only FDA-approved GA treatment that consistently demonstrated ...

JPMorgan says Astellas Pharma’s (ALPMY) (ALMPY) announcement that the FDA has issued a Complete Response Letter regarding for Izervay in ...

Izervay (avacincaptad pegol) has been cleared by the US regulator for GA secondary to age-related macular degeneration (AMD), a leading form of blindness, setting up a market clash with Apellis ...

While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.

These injections deliver medication such as the new geographic atrophy drugs Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), powerful anti-VEGFs (vascular endothelial growth factor) to keep ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

Sales of Strategic Brands supporting our future growth namely PADCEV, IZERVAY, VEOZAH, VYLOY, and XOSPATA expanded to over 150 billion yen in total with a robust growth of additional 90 billion ...